IONIS PHARMACEUTICALS INC (IONS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 452,049 | - | 133,814 | 225,250 |
| Selling, general and administrative | 90,622 | - | 61,638 | 65,113 |
| Cost of sales | 4,151 | - | 1,071 | 4,164 |
| Research, development and patent | 217,460 | - | 219,761 | 222,064 |
| Total operating expenses | 312,233 | - | 282,470 | 291,341 |
| Income (loss) from operations | 139,816 | -146,860 | -148,656 | -66,091 |
| Investment income | 24,687 | 24,667 | 26,228 | 25,599 |
| Interest expense | 4,114 | 4,108 | 4,161 | 4,490 |
| Loss on investments, net | -18,312 | -2,164 | 879 | -3,533 |
| Interest expense related to sale of future royalties | 18,648 | 18,822 | 18,533 | 18,296 |
| Other income, net | 102 | 465 | 142 | 610 |
| Income (loss) before income tax benefit (expense) | 123,531 | -146,822 | -144,101 | -66,201 |
| Income tax benefit (expense) | -20 | 116 | -3,621 | 64 |
| Net income (loss) | 123,551 | -146,938 | -140,480 | -66,265 |
| Basic net income (loss) per share (in dollars per share) | 0.78 | -0.93 | -0.95 | -0.45 |
| Diluted net income (loss) per share (in dollars per share) | 0.7 | -0.93 | -0.95 | -0.45 |
| Shares used in computing basic net income (loss) per share (in shares) | 159,137,000 | 158,735,000 | 148,593,000 | 145,958,000 |
| Shares used in computing diluted net income (loss) per share (in shares) | 182,331,000 | 158,735,000 | 148,593,000 | 145,958,000 |